{
  "findings": [
    {
      "id": "Q01",
      "metric": "Fraction of tumor proteins represented in immunopeptidome",
      "value": "62.3%",
      "comparator_or_baseline": "37.3% (baseline)",
      "interpretation": "Broader antigen display after intratumoral mRNA vaccination indicates enhanced peptide presentation capacity.",
      "evidence_line_refs": ["L28"]
    },
    {
      "id": "Q02",
      "metric": "Fraction of proteins represented in MHC-I peptidome",
      "value": "40.6%",
      "comparator_or_baseline": "20.6% (baseline)",
      "interpretation": "Strong expansion of MHC-I-presented landscape demonstrates that mRNA vaccination increases tumor antigen visibility to CD8+ T cells.",
      "evidence_line_refs": ["L29"]
    },
    {
      "id": "Q03",
      "metric": "Retrospective human survival comparison p-value",
      "value": "p=0.01",
      "comparator_or_baseline": "N/A",
      "interpretation": "Vaccinated subgroup had statistically improved survival under ICI treatment compared to unvaccinated patients.",
      "evidence_line_refs": ["L30"]
    },
    {
      "id": "Q04",
      "metric": "Type I interferon response score (normalized units)",
      "value": "3.1",
      "comparator_or_baseline": "1.0 (baseline)",
      "interpretation": "Marked induction of type I interferon response after mRNA vaccination in tumors confirms robust innate immune activation.",
      "evidence_line_refs": ["L31"]
    },
    {
      "id": "Q05",
      "metric": "PD-L1 expression fold-change in tumor tissue",
      "value": "2.4x",
      "comparator_or_baseline": "1.0x (baseline)",
      "interpretation": "Checkpoint axis became more targetable, providing rationale for combining mRNA vaccination with PD-L1 blockade.",
      "evidence_line_refs": ["L32"]
    },
    {
      "id": "Q06",
      "metric": "Intratumoral CD8+ T-cell density fold-change",
      "value": "1.8x",
      "comparator_or_baseline": "1.0x (baseline)",
      "interpretation": "Increased immune infiltration with combination therapy demonstrates enhanced anti-tumor immune response.",
      "evidence_line_refs": ["L33"]
    }
  ],
  "controls_or_null_results": [
    {
      "statement": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
      "evidence_line_ref": "L36"
    },
    {
      "statement": "ICI-only treatment had limited activity in low-immunogenic baseline settings.",
      "evidence_line_ref": "L37"
    },
    {
      "statement": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect, confirming the mRNA component is essential.",
      "evidence_line_ref": "L38"
    },
    {
      "statement": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, proving interferon signaling is mechanistically required.",
      "evidence_line_ref": "L39"
    }
  ]
}